๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Fuzhou
Clinical trial register · China

Clinical Trials in Fuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 8 Guangzhou 8 Tianjin 6 Zhengzhou 4 Fuzhou 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing8 Guangzhou8 Tianjin6 Zhengzhou4 Fuzhou3
All 27 locations
Target enrolment
to

Trials with a site in Fuzhou

3 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Beijing, Fuzhou, Guangzhou, Zhengzhou, Nanjing, Tianjin, Hanzhou
2024-05-24
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 3
606
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing
2023-01-10
Rows per page Showing 1–3 of 3
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/fuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3 of those studies with a site in Fuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Fuzhou?

1 of the 3 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Fuzhou), 3 studies
PhaseStudiesRecruitingShare
Phase 32066.7%
Phase 11133.3%

Most active sponsors

Lead sponsors with the most studies (Fuzhou)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb10
Janssen Research & Development, LLC10
Jiangsu Simcere Pharmaceutical Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.